Article
Oncology
Minran Zhou, Xiaolin Yin, Lixin Zheng, Yue Fu, Yue Wang, Zelong Cui, Zhenxing Gao, Xiaoming Wang, Tao Huang, Jihui Jia, Chunyan Chen
Summary: Overall, the study found that miR-181d overexpression in CML-BP promotes leukemia cell proliferation. RBP2 was identified as a direct target of miR-181d, inhibiting RBP2 expression and subsequently affecting NF-kappa B p65 transcriptional expression. This feedback regulation contributes to sustained NF-kappa B activation in the development of CML-BP.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Jusuf Imeri, Christophe Desterke, Paul Marcoux, Gladys Telliam, Safa Sanekli, Sylvain Barreau, Yucel Erbilgin, Theodoros Latsis, Patricia Hugues, Nathalie Sorel, Emilie Cayssials, Jean-Claude Chomel, Annelise Bennaceur-Griscelli, Ali G. Turhan
Summary: The study aims to model CML progression and generate a BC-CML model in vitro in order to identify new targets. One of the CML-iPSCs generated myeloid blasts after hematopoietic differentiation, exhibiting monoblastic patterns and expressing cMPO, CD45, CD34, CD33, and CD13. Single-cell transcriptomics revealed a delayed differentiation in the mutated condition and increased levels of MSX1, while CD45 and CD41 levels decreased.
Letter
Oncology
Jeremy W. Jacobs, Rahul Ramaswamy, Vanessa States, Jennifer Reppucci, Olalekan O. Oluwole, Emily F. Mason, Mary Ann Thompson
Summary: Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 oncogene and can often be controlled by tyrosine kinase inhibitors. CML may progress to an acute leukemia, with blast crises typically of myeloid or lymphoid lineage but rarely purely erythroid. Pure erythroid leukemia arising from a CML blast crisis is rare, with only two definitive cases reported.
LEUKEMIA & LYMPHOMA
(2022)
Review
Oncology
Lulu Wang, Li Li, Rongrong Chen, Xianbo Huang, Xiujin Ye
Summary: CML is primarily caused by the t(9;22) translocation, resulting in the BCR-ABL fusion gene. Molecular mechanisms such as genetic aberrations, telomere biology, and epigenetic anomalies contribute to blast transformation of CML. Treatment options and outcomes are limited, with regular monitoring and risk-adapted therapeutic strategies being crucial in improving patient survival and quality of life.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Multidisciplinary Sciences
Bin Zhang, Dandan Zhao, Fang Chen, David Frankhouser, Huafeng Wang, Khyatiben V. Pathak, Lei Dong, Anakaren Torres, Krystine Garcia-Mansfield, Yi Zhang, Dinh Hoa Hoang, Min-Hsuan Chen, Shu Tao, Hyejin Cho, Yong Liang, Danilo Perrotti, Sergio Branciamore, Russell Rockne, Xiwei Wu, Lucy Ghoda, Ling Li, Jie Jin, Jianjun Chen, Jianhua Yu, Michael A. Caligiuri, Ya-Huei Kuo, Mark Boldin, Rui Su, Piotr Swiderski, Marcin Kortylewski, Patrick Pirrotte, Le Xuan Truong Nguyen, Guido Marcucci
Summary: The mechanisms underlying the transformation of chronic phase (CP) to blast crisis (BC) in chronic myeloid leukemia (CML) are not fully understood. This study reveals that deficiency of miR-142 drives the progression of CML to BC by regulating mitochondrial metabolism, and it may serve as a potential therapeutic target to prevent BC in CML.
NATURE COMMUNICATIONS
(2023)
Review
Biochemistry & Molecular Biology
Binoy Yohannan, Binsah George
Summary: This article provides a comprehensive summary of the current management of Lymphoid Blast Crisis (BC), which is one of the most feared complications of chronic myeloid leukemia (CML). The incidence of BC has significantly decreased in the BCR-ABL tyrosine kinase inhibitor era, but there is still a need for novel therapies to improve the clinical outcomes of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Anupama Ninawe, Sameer Ahmad Guru, Prasant Yadav, Mirza Masroor, Amit Samadhiya, Namrata Bhutani, Naresh Gupta, Richa Gupta, Alpana Saxena
Summary: The study reveals alterations in the expression levels of miR-486-5p in CML patients, suggesting its potential as a biomarker for diagnosis and prognosis. The findings indicate a critical role of miR-486-5p in the treatment and prognosis of CML patients.
Article
Oncology
Ya-Ru Miao, Wen Liu, Zhaodong Zhong, Yong You, Yutong Tang, Weiming Li, Xiaojian Zhu, An-Yuan Guo
Summary: In this study, a CML patient experienced a sudden lymphoid blast crisis after a long treatment-free remission. Mutations in TGFBR2 and PCNT were identified as potentially accelerating B cell transformation, and single-cell transcriptome data revealed clone evolution. The patient achieved remission through CAR-T therapy after failing multiple lines of treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medical Laboratory Technology
Yi Dong, Jia Wang, Yuanyuan Shen, Qing Zhang, Zhimin Zhai, Qianshan Tao
Summary: Isolated CNS blast crisis in CML is rare, especially with dasatinib treatment. The use of various diagnostic methods, including imaging, immunophenotyping, and PCR, is crucial for evaluating and managing such cases. The identification of blast cells using flow cytometry is important for determining the extent of CNS involvement.
CLINICAL LABORATORY
(2021)
Article
Cell Biology
Jinhua He, Zeping Han, Ziyi An, Yumin Li, Xingyi Xie, Jiabin Zhou, Sihua He, Yubing Lv, Mengling He, Hong Qu, Gexiu Liu, Yuguang Li
Summary: The research demonstrates that EGR1 positively regulates the expression of miR-203a, which in turn affects the regulation of target genes including WT1, BMI1, and XIAP, ultimately influencing the proliferation of CML cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Golnaz Ensieh Kazemi-Sefat, Mohammad Keramatipour, Mohammad Vaezi, Seyed Mohsen Razavi, Kaveh Kavousi, Amin Talebi, Shahrbanoo Rostami, Marjan Yaghmaei, Bahram Chahardouli, Saeed Talebi, Kazem Mousavizadeh
Summary: This study identified important genetic variants in patients with myeloid blast crisis chronic myeloid leukemia (CML) using integrated genomic sequencing. These variants affect genes involved in leukemia stem cell proliferation, self-renewal, and differentiation. RNA sequencing was used to confirm these variants. This approach provides insights into the pathophysiology of CML and may aid in its management.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Aviraag Vijaya Prakash, Keerthana P. Sivakolundu, Natasha M. Savage, Vamsi K. Kota, Mahran Shoukier
Summary: Sudden blast crisis in CML patients being treated with TKIs is uncommon but significant. Improving drug selection and careful monitoring can help prevent such unfortunate outcomes.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Oncology
Annemarie Schwarz, Ingo Roeder, Michael Seifert
Summary: Chronic myeloid leukemia (CML) is a slowly progressing blood cancer that primarily affects elderly people. Targeted therapies have led to long-term disease control for most patients, but some still do not respond well to treatment. In this study, we analyzed gene expression profiles of the three phases of CML and identified characteristic gene expression alterations and signaling pathway changes. This analysis provides insights into the molecular characterization of the different CML phases and may help in developing additional treatment strategies.
Article
Biochemistry & Molecular Biology
Lucia Vrablova, Vladimir Divoky, Pavla Koralkova, Katerina Machova Polakova, Eva Kriegova, Romana Janska, Jan Grohmann, Milena Holzerova, Tomas Papajik, Edgar Faber
Summary: This article reports on two patients with lymphoid BC CML who were unable to undergo allogeneic stem cell transplantation. Instead, they received chemotherapy in combination with rituximab, imatinib, and dasatinib, achieving deep molecular response. These results suggest a re-evaluation of the use of combination drug therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Shady Adnan-Awad, Matti Kankainen, Satu Mustjoki
Summary: The BCR-ABL1 fusion gene is a hallmark of CML, and TKIs have greatly improved its management. Challenges in the TKI era include patient stratification, frontline TKI selection, and Treatment-Free Remission. Incorporating genetic data in treatment decisions shows promise for high-risk CML patients.
LEUKEMIA & LYMPHOMA
(2021)
